These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

186 related articles for article (PubMed ID: 24362621)

  • 1. Modified GTX as second-line therapy for advanced pancreatic adenocarcinoma.
    Ajouz H; Mukherji D; Haydar A; Yakan AS; Saleh A; Elias E; Temraz S; Faraj W; Khalife M; Shamseddine A
    J Gastrointest Cancer; 2014 Mar; 45(1):109-12. PubMed ID: 24362621
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Docetaxel second-line therapy in patients with advanced pancreatic cancer: a retrospective study.
    Saif MW; Syrigos K; Penney R; Kaley K
    Anticancer Res; 2010 Jul; 30(7):2905-9. PubMed ID: 20683031
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A multicenter analysis of GTX chemotherapy in patients with locally advanced and metastatic pancreatic adenocarcinoma.
    De Jesus-Acosta A; Oliver GR; Blackford A; Kinsman K; Flores EI; Wilfong LS; Zheng L; Donehower RC; Cosgrove D; Laheru D; Le DT; Chung K; Diaz LA
    Cancer Chemother Pharmacol; 2012 Feb; 69(2):415-24. PubMed ID: 21800112
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The gemcitabine, docetaxel, and capecitabine (GTX) regimen for metastatic pancreatic cancer: a retrospective analysis.
    Fine RL; Fogelman DR; Schreibman SM; Desai M; Sherman W; Strauss J; Guba S; Andrade R; Chabot J
    Cancer Chemother Pharmacol; 2008 Jan; 61(1):167-75. PubMed ID: 17440727
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A randomized phase II trial of two different 4-drug combinations in advanced pancreatic adenocarcinoma: cisplatin, capecitabine, gemcitabine plus either epirubicin or docetaxel (PEXG or PDXG regimen).
    Reni M; Cereda S; Rognone A; Belli C; Ghidini M; Longoni S; Fugazza C; Rezzonico S; Passoni P; Slim N; Balzano G; Nicoletti R; Cappio S; Doglioni C; Villa E
    Cancer Chemother Pharmacol; 2012 Jan; 69(1):115-23. PubMed ID: 21626049
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Two cases of advanced pancreas cancer treated with GTX: combined use of gemcitabine, docetaxel and capecitabine].
    Honda K; Fukuhara T; Kojima Y; Tanaka H; Kushihata F; Kobayashi N
    Gan To Kagaku Ryoho; 2006 Dec; 33(13):2089-92. PubMed ID: 17197760
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A phase I study of the biomodulation of capecitabine by docetaxel and gemcitabine (mGTX) in previously untreated patients with metastatic adenocarcinoma of the pancreas.
    Hill ME; Li X; Kim S; Campbell A; Culler K; Bloomston M; Zalupski M; Hejna G; Bekaii-Saab T
    Cancer Chemother Pharmacol; 2011 Mar; 67(3):511-7. PubMed ID: 20461379
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Predictors of Response and Survival in Locally Advanced Adenocarcinoma of the Pancreas Following Neoadjuvant GTX with or Without Radiation Therapy.
    Sherman WH; Hecht E; Leung D; Chu K
    Oncologist; 2018 Jan; 23(1):4-e10. PubMed ID: 29212734
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Neoadjuvant gemcitabine, docetaxel, and capecitabine followed by gemcitabine and capecitabine/radiation therapy and surgery in locally advanced, unresectable pancreatic adenocarcinoma.
    Sherman WH; Chu K; Chabot J; Allendorf J; Schrope BA; Hecht E; Jin B; Leung D; Remotti H; Addeo G; Postolov I; Tsai W; Fine RL
    Cancer; 2015 Mar; 121(5):673-80. PubMed ID: 25492104
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Capecitabine plus erlotinib in gemcitabine-refractory advanced pancreatic cancer.
    Kulke MH; Blaszkowsky LS; Ryan DP; Clark JW; Meyerhardt JA; Zhu AX; Enzinger PC; Kwak EL; Muzikansky A; Lawrence C; Fuchs CS
    J Clin Oncol; 2007 Oct; 25(30):4787-92. PubMed ID: 17947726
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Modified docetaxel and cisplatin in combination with capecitabine (DCX) as a first-line treatment in HER2-negative advanced gastric cancer.
    Bilici A; Selcukbiricik F; Demir N; Oven Ustaalioglu BB; Dikilitas M; Yildiz O
    Asian Pac J Cancer Prev; 2014; 15(20):8661-6. PubMed ID: 25374186
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The use of GTX as second-line and later chemotherapy for metastatic pancreatic cancer: a retrospective analysis.
    Dakik HK; Moskovic DJ; Carlson PJ; Tamm EP; Qiao W; Wolff RA; Abbruzzese JL; Fogelman DR
    Cancer Chemother Pharmacol; 2012 Feb; 69(2):425-30. PubMed ID: 21850466
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Safety and Efficacy of Gemcitabine, Docetaxel, Capecitabine, Cisplatin as Second-line Therapy for Advanced Pancreatic Cancer After FOLFIRINOX.
    Fumet JD; Vincent J; Bengrine L; Hennequin A; Granconato L; Palmier R; Ghiringhelli F
    Anticancer Res; 2020 Jul; 40(7):4011-4015. PubMed ID: 32620645
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Randomized phase II study of gemcitabine administered at a fixed dose rate or in combination with cisplatin, docetaxel, or irinotecan in patients with metastatic pancreatic cancer: CALGB 89904.
    Kulke MH; Tempero MA; Niedzwiecki D; Hollis DR; Kindler HL; Cusnir M; Enzinger PC; Gorsch SM; Goldberg RM; Mayer RJ
    J Clin Oncol; 2009 Nov; 27(33):5506-12. PubMed ID: 19858396
    [TBL] [Abstract][Full Text] [Related]  

  • 15. First line treatment for metastatic pancreatic adenocarcinoma: looking for the step forward.
    Ramfidis VS; Psyrri A; Syrigos KN; Saif MW
    JOP; 2014 Jul; 15(4):286-8. PubMed ID: 25076321
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A phase II study of capecitabine plus docetaxel in gemcitabine-pretreated metastatic pancreatic cancer patients: CapTere.
    Soares HP; Bayraktar S; Blaya M; Lopes G; Merchan J; Macintyre J; Mayo C; Green MR; Silva O; Levi J; Walker G; Rocha-Lima CM
    Cancer Chemother Pharmacol; 2014 Apr; 73(4):839-45. PubMed ID: 24562589
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Neoadjuvant chemoradiation to convert locally advanced pancreatic body adenocarcinoma to resectable disease.
    Cunningham SC; Cusnir M; Burdick RK; Van Echo DA; Moesinger R
    Clin Adv Hematol Oncol; 2003 Dec; 1(12):741-2; discussion 743. PubMed ID: 16258479
    [No Abstract]   [Full Text] [Related]  

  • 18. Phase III randomized comparison of gemcitabine versus gemcitabine plus capecitabine in patients with advanced pancreatic cancer.
    Cunningham D; Chau I; Stocken DD; Valle JW; Smith D; Steward W; Harper PG; Dunn J; Tudur-Smith C; West J; Falk S; Crellin A; Adab F; Thompson J; Leonard P; Ostrowski J; Eatock M; Scheithauer W; Herrmann R; Neoptolemos JP
    J Clin Oncol; 2009 Nov; 27(33):5513-8. PubMed ID: 19858379
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Combining gemcitabine, oxaliplatin and capecitabine (GEMOXEL) for patients with advanced pancreatic carcinoma (APC): a phase I/II trial.
    Hess V; Pratsch S; Potthast S; Lee L; Winterhalder R; Widmer L; Cescato C; Lohri A; Jost L; Stillhart P; Pestalozzi B; Herrmann R
    Ann Oncol; 2010 Dec; 21(12):2390-2395. PubMed ID: 20444846
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Second-line chemotherapy with capecitabine (Xeloda) and docetaxel (Taxotere) in previously treated, unresectable adenocarcinoma of pancreas: the final results of a phase II trial.
    Katopodis O; Polyzos A; Kentepozidis N; Giassas S; Rovithi M; Bozionelou V; Kalbakis K; Vamvakas L; Mavroudis D; Georgoulias V
    Cancer Chemother Pharmacol; 2011 Feb; 67(2):361-8. PubMed ID: 20428874
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.